John H. Abeles, M.D. joined the Scientific Advisory Board of CombiMatrix in 2006. Dr. Abeles practiced Medicine in London, before joining the Pharmaceutical Industry as a Senior Medical Executive, with Pfizer, Inc., Sterling Drug, and Revlon Health Care. From 1975 until 1980, he was a healthcare analyst with Kidder Peabody and later formed MedVest Inc., a healthcare consulting firm. Since 1992, Dr. Abeles has been a Founder and investor in several investment funds for both venture capital and public equities, whose investments were centered around healthcare and medical equipment companies. He also presently serves as a Managing Member of a New York based investment fund focused on healthcare investments.

Dr. Abeles presently serves on the board of directors for I-Flow Corporation (Nasdaq: IFLO), DUSA Pharmaceuticals (Nasdaq: DUSA), CytoCore, Inc. (Nasdaq: MCDG) and Oryx Technology (Nasdaq: ORYX). Dr. Abeles also serves as an Advisory Board Member of the College of Chemistry, University of California, Berkeley, and is on the Advisory Board of the Higuchi BioSciences Institute at the University of Kansas.

Dr. Abeles received his Medical degree as well as a degree in Pharmacology from the University of Birmingham, England, in 1969. He is a Fellow of the Royal Society of Medicine, London.

Dr. Grey was awarded his Ph.D. in 1995 from Monash University where he characterized a novel cellular signaling pathway regulating the human inflammatory response. Dr. Grey was then recruited to the Novartis Center for Immunobiology in Boston where he conducted his post-doctoral training in the areas of human immunology, gene therapy, and transplantation.

Dr. Shane T. Grey was appointed Assistant Professor in Surgery at Harvard Medical School's Department of Surgery in 2001. Dr. Grey's research focused on utilizing novel, state-of-the-art gene-based therapies to treat important inflammatory diseases. This includes the treatment of autoimmune deficiencies and other conditions such as diabetes mellitus, a significant cause of suffering in our present day community.

Dr. Grey currently sits on invited review boards for national and international funding agencies and scientific journals. These include the Juvenile Diabetes Foundation International, the National Health and Medical Research Council of Australia, and journals including Journal of Immunology and Immunology Today. He has been awarded the Juvenile Diabetes Foundations internationally acclaimed Career Development Award. This 750,000 (USD) research prize is awarded each year to eminent scientists in the field of Type I diabetes research. This was awarded to Dr Grey for his outstanding work in diabetes and to promote development of his novel gene-based therapeutics to treat Type I diabetes mellitus. In August 2003, Dr. Grey was awarded the "BioFirst Award," a prize given to only two internationally recognized scientists each year to recruit and promote biotechnology research in Australia.

In August of 2004, Dr. Grey moved his research to the prestigious, internationally recognized Garvan Institute of Medical Research in Sydney Australia www.garvan.org.au. This institute is a leader in gene-based medical research, promoting integrated disease focused research that aims to discover the molecular basis for disease.

Dr. Kay's areas of specialty include work in RNAi, gene therapy, nucleic-acid drug delivery, and viral inhibition. He was the first to develop and demonstrate the efficacy of siRNA in mammals, and his work on the use of siRNA to inhibit hepatitis B is considered a seminal step in the advancement of this technology. He and his laboratory at the Stanford University School of Medicine are devoted to research on methods for controlling gene expression levels as a means to treat disease. Current emphasis is on hemophilia, human hepatitis virus infection, and diabetes, but the techniques are widely applicable to a large number of other diseases. For hemophilia, the approaches are currently in Phase I/II trials. For hepatitis B and C, they have developed RNAi approaches in animal models and are developing a therapy suitable for humans.

Dr. Kay is Professor, Departments of Pediatrics and Genetics, and Director, Program in Human Gene Therapy, at the Stanford University School of Medicine. Dr. Kay is one of the founders and currently the Vice President of the American Society of Gene Therapy. Prior to that, from 1993 to 1998, he was in the Department of Medicine at the University of Washington. Dr. Kay completed his internship and residency in 1990 and then did postdoctoral work in gene therapy from 1990 to 1993 at Baylor College of Medicine. Dr. Kay received a B.S. degree from Michigan State University, and a Ph.D. and a M.D. from Case Western Reserve University.

He is an author of over 100 articles, manuscripts, and book chapters, a frequently invited lecturer, and the recipient of several honors including, in 2000, the E. Mead Johnson Award for Pediatric Researcher of the Year and the National Hemophilia Foundation Researcher of the Year.

F. Mark Modzelewski is Founder and Principal of the Benet Group which helps develop nanotechnology ventures. He is also the Founder of The NanoBusiness Alliance (www.nanobusiness.org). The Alliance's mission is to create a collective voice for the emerging small tech industry, and develop a range of initiatives to support and strengthen the nanotechnology business community. This includes research and education, public policy, public awareness and relations, and industry support and development efforts.

Mark is also a member of the Nanotechnology Technical Advisory Group to President Bush's Council of Advisors on Science and Technology (PCAST). He is among the most well known figures in the nanotech field and was recently recognized by Forbes Magazine as one of nanotech's top 5 "powerbrokers" and received a Small Times Best of Small Tech Awards. He is a finalist for this year's Fortune Magazine "40 Under 40." Mark has testified before the US Senate on nanotechnology funding, investment, technology transfer, and global competition. He also developed partnerships for the Alliance with Deloitte & Touche, Penton Media, Nissho Iwai and others to develop reports, events, mentor start-ups, and enter new markets. He also structured affiliate organizations and regional nanobusiness "hubs" in the EU, Canada, Israel, and a dozen US states.

Mark has lectured at numerous global technology and investor conferences, leading think tanks, as well as briefing the White House, US Dept. of Commerce, NSF, Congress, the Federal Reserve's Financial Markets retreat, global Fortune 500 companies, and a multitude of foreign government agencies.

Mark was previously an appointee in the Clinton Administration, which he served as Special Assistant to Sec. Henry Cisneros at HUD and Sec. Dan Glickman of USDA. He is a graduate of the University of Denver College of Law and Boston University.

In the late 1970's, Dr. Camran Nezhat introduced a technique that would revolutionize modern-day abdominal, pelvic, and chest surgery. By attaching a video camera to a laparoscope, he started to operate from a comfortable, upright position, watching the TV monitors, rather than bent over, peering with one eye through the lens of a scope. By placing monitors around the operating room, the entire staff could now observe and participate in the procedure. This evolved into the techniques known now as Videolaparoscopy and Video-Assisted Surgery.

The surgical techniques of Video laparoscopy require only a few small incisions, dramatically reducing pain and recovery time compared to earlier, conventional open surgery (laparotomy), in which very large incisions are generally required. In addition, through sharing his expertise with other surgical specialists, Dr. Nezhat has been instrumental in assisting with the adaptation and advancement of minimally invasive surgery for such disciplines as thoracic, urologic, neurological, gastroenterological, and other general surgeries. By constantly seeking to perfect surgery, and to minimize discomfort and complications for patients, he has gone on to perform and develop many other innovative surgeries laparoscopically for the first time, some of which were previously considered impossible.

Chairman and CEO Roberto Rosenkranz, Ph.D., M.B.A, co-founded Roxro Pharma, LLC. Dr. Rosenkranz' experience in the pharmaceutical industry spans nearly 20 years, encompassing both science and business. He held positions in pharmacology, new product development, market research, sales, managed care, and business development at Syntex Corporation. He then served as Director of Business Operations for Roche Laboratories. Most recently, he was President and Chief Operating Officer of Scios Inc., a public biopharmaceutical company. Dr. Rosenkranz has served on the board of directors of both public and private companies, including Gemini Genomics PLC, prior to its merger with Sequenom, Inc. He currently serves on the board of directors of Pherin Pharmaceuticals. Dr. Rosenkranz holds a B.A. in psychology from Stanford University, a Ph.D. in pharmacology and toxicology from the University of California at Davis, and an M.B.A. from Santa Clara University. He is the author of over 70 scientific papers and abstracts, and holds six patents.

Roger L. Whiting, Ph.D., is a founder and, since October 1999, the President and Chief Scientific Officer of Roxro Pharma LLC, a pharmaceutical company. From July 1995 to September 1999, Dr. Whiting was the Senior Vice President of the Neurobiology Business Unit of Roche Bioscience, a division of Syntex (U.S.A.) Inc., a pharmaceutical research company. Dr. Whiting received a bachelor's degree from the University of Bradford, UK and his Ph.D. from Aston University, UK.